Nuveen
VRCA icon

Nuveen’s Verrica Pharmaceuticals VRCA Stock Holding History

Nuveen’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-9,503
Closed -$138K – 3345
2024
Q3 		$138K Hold
9,503
– – ﹤0.01% 3280
2024
Q2 		$693K Hold
9,503
– – ﹤0.01% 2882
2024
Q1 		$563K Hold
9,503
– – ﹤0.01% 2935
2023
Q4 		$696K Hold
9,503
– – ﹤0.01% 2889
2023
Q3 		$369K Hold
9,503
– – ﹤0.01% 2929
2023
Q2 		$548K Buy
+9,503
New +$577K ﹤0.01% 2893
2022
Q2 		– Sell
-3,279
Closed -$277K – 3494
2022
Q1 		$277K Hold
3,279
– – ﹤0.01% 3137
2021
Q4 		$297K Hold
3,279
– – ﹤0.01% 3181
2021
Q3 		$399K Hold
3,279
– – ﹤0.01% 3208
2021
Q2 		$371K Hold
3,279
– – ﹤0.01% 3195
2021
Q1 		$497K Sell
3,279
-1,426
-30% -$197K ﹤0.01% 3100
2020
Q4 		$542K Buy
4,705
+79
+2% +$7.26K ﹤0.01% 3025
2020
Q3 		$358K Buy
4,626
+395
+9% +$32.4K ﹤0.01% 3040
2020
Q2 		$466K Sell
4,231
-806
-16% -$93.2K ﹤0.01% 2929
2020
Q1 		$550K Buy
5,037
+410
+9% +$54K ﹤0.01% 2732
2019
Q4 		$735K Buy
4,627
+251
+6% +$37K ﹤0.01% 2796
2019
Q3 		$646K Buy
4,376
+2,377
+119% +$265K ﹤0.01% 2866
2019
Q2 		$232K Buy
+1,999
New +$188K ﹤0.01% 3162

Other funds holding VRCA

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SA
Sovran Advisors San Diego, California $1.34B AUM 21.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nuveen's VRCA Position: Q4 2024 in Review

Nuveen sold out of Verrica Pharmaceuticals (VRCA) in Q4 2024, closing a stake of 9,503 shares — an estimated $138K sold.

Nuveen first reported a position in VRCA in Q2 2019 and held it in 18 quarters. The position peaked at $735K in Q4 2019. 81 funds tracked by Wall St. Rank hold VRCA as of Q4 2024.

  • Nuveen reported no remaining Verrica Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Nuveen sold 9,503 Verrica Pharmaceuticals shares in Q4 2024, an estimated $138K.
  • Nuveen first reported a position in Verrica Pharmaceuticals in Q2 2019 and held it in 18 quarters.
  • Nuveen's Verrica Pharmaceuticals position peaked at $735K in Q4 2019.
  • 81 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q4 2024.

Based on Nuveen's 13F filing for Q4 2024, filed 14 Feb 2025.